Seeking Alpha

Eli Lilly's (LLY +0.9%) Phase III Pointbreak trial did not meet its primary endpoint of improved...

Eli Lilly's (LLY +0.9%) Phase III Pointbreak trial did not meet its primary endpoint of improved overall survival in lung-cancer patients, although it did meet a secondary goal of improved progression-free survival for the Alimta arm. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)